Research Analysts Set Expectations for ATXS FY2025 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Astria Therapeutics in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biotechnology company will post earnings of ($1.98) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share.

A number of other research firms have also issued reports on ATXS. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Wedbush restated an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Finally, JMP Securities initiated coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Astria Therapeutics presently has an average rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Stock Up 3.9 %

Shares of NASDAQ:ATXS traded up $0.20 during trading on Thursday, hitting $5.36. 408,704 shares of the company traded hands, compared to its average volume of 363,361. The business's fifty day moving average is $5.40 and its 200-day moving average is $7.88. The stock has a market capitalization of $302.49 million, a price-to-earnings ratio of -2.56 and a beta of 0.45. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01.

Hedge Funds Weigh In On Astria Therapeutics

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in shares of Astria Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock valued at $556,000 after acquiring an additional 1,381 shares during the period. Hsbc Holdings PLC increased its position in shares of Astria Therapeutics by 9.0% during the 4th quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company's stock valued at $170,000 after purchasing an additional 1,587 shares during the period. Legal & General Group Plc raised its stake in shares of Astria Therapeutics by 7.6% in the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company's stock worth $281,000 after buying an additional 2,222 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after buying an additional 2,766 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Astria Therapeutics by 19.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock valued at $159,000 after buying an additional 2,878 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.